Literature DB >> 35066810

Iron metabolism protein transferrin receptor 1 involves in cervical cancer progression by affecting gene expression and alternative splicing in HeLa cells.

Nan Huang1, Yaxun Wei2, Yi Cheng3, Xiaolong Wang1, Qi Wang2,4, Dong Chen2,4, Wenjing Li5.   

Abstract

BACKGROUND: Transferrin receptor 1 (TfR1), encoded by TFRC, is a key regulator of iron homeostasis and plays important roles in many diseases, including cancers.
OBJECTIVE: To decipher the underlying molecular functions of TfR1 based on its influence on transcriptome profile in cancer cells.
METHODS: In this study, we first identified the expression pattern and prognostic influence of TFRC in cervical cancer patients from TCGA database. To explore the regulatory outcomes of TfR1 from the view of whole transcriptome profile, we generated TFRC knockdown (TFRC-KD) HeLa cells and negative control (NC) cells using short hairpin RNA (shRNA) method. Unbiased transcriptome sequencing (RNA-seq) experiment was used to analyze the global expression level and alternative splicing (AS) changes between TFRC-KD and NC cells.
RESULTS: We found TFRC was consistently elevated in cervical cancer samples and tightly associated with prognosis of patients. Differential expression analysis revealed that 629 differentially expressed genes (DEGs) were identified between TFRC-KD and NC. Functional enrichment analysis of these DEGs revealed that TFRC-KD extensively disturbed cell physiology related pathways, including immunity, cell metabolism and gene expression. Moreover, dysregulated AS profile also indicated that TfR1 has important roles in the AS regulation. Hundreds of TfR1-regulated AS genes were involved in DNA repair, cell death, transcription and viral reproduction pathways, which were tightly associated with cancer cell progression.
CONCLUSIONS: In summary, we for the first time explored the molecular functions of TfR1 at transcriptional and post-transcriptional levels. These results demonstrate TfR1 participates in the progression of cervical cancer by affecting the expression and AS levels of genes in cancer associated pathways, which greatly extends our understanding of TfR1 functions besides iron homeostasis and provide novel options in cancer treatment by targeting TfR1.
© 2021. The Author(s) under exclusive licence to The Genetics Society of Korea.

Entities:  

Keywords:  Alternative splicing; Cell physiology; Gene expression; RNA-seq; TFR1

Mesh:

Substances:

Year:  2022        PMID: 35066810     DOI: 10.1007/s13258-021-01205-w

Source DB:  PubMed          Journal:  Genes Genomics        ISSN: 1976-9571            Impact factor:   1.839


  51 in total

1.  Transferrin receptor 1 controls systemic iron homeostasis by fine-tuning hepcidin expression to hepatocellular iron load.

Authors:  Carine Fillebeen; Edouard Charlebois; John Wagner; Angeliki Katsarou; Jeannie Mui; Hojatollah Vali; Daniel Garcia-Santos; Prem Ponka; John Presley; Kostas Pantopoulos
Journal:  Blood       Date:  2018-12-11       Impact factor: 22.113

Review 2.  Context-dependent control of alternative splicing by RNA-binding proteins.

Authors:  Xiang-Dong Fu; Manuel Ares
Journal:  Nat Rev Genet       Date:  2014-08-12       Impact factor: 53.242

Review 3.  Recent advances in iron metabolism and related disorders.

Authors:  Clara Camaschella; Paolo Strati
Journal:  Intern Emerg Med       Date:  2010-04-28       Impact factor: 3.397

Review 4.  RNA-binding proteins in Mendelian disease.

Authors:  Alfredo Castello; Bernd Fischer; Matthias W Hentze; Thomas Preiss
Journal:  Trends Genet       Date:  2013-02-15       Impact factor: 11.639

Review 5.  Overview of iron metabolism in health and disease.

Authors:  Som Dev; Jodie L Babitt
Journal:  Hemodial Int       Date:  2017-03-15       Impact factor: 1.812

6.  Insights into RNA biology from an atlas of mammalian mRNA-binding proteins.

Authors:  Alfredo Castello; Bernd Fischer; Katrin Eichelbaum; Rastislav Horos; Benedikt M Beckmann; Claudia Strein; Norman E Davey; David T Humphreys; Thomas Preiss; Lars M Steinmetz; Jeroen Krijgsveld; Matthias W Hentze
Journal:  Cell       Date:  2012-05-31       Impact factor: 41.582

Review 7.  Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches.

Authors:  Mo Chen; James L Manley
Journal:  Nat Rev Mol Cell Biol       Date:  2009-09-23       Impact factor: 94.444

8.  Iron availability modulates aberrant splicing of ferrochelatase through the iron- and 2-oxoglutarate dependent dioxygenase Jmjd6 and U2AF(65.).

Authors:  Jasmin Barman-Aksözen; Chantal Béguin; Afzal M Dogar; Xiaoye Schneider-Yin; Elisabeth I Minder
Journal:  Blood Cells Mol Dis       Date:  2013-06-18       Impact factor: 3.039

Review 9.  Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology.

Authors:  Rikki A M Brown; Kirsty L Richardson; Tasnuva D Kabir; Debbie Trinder; Ruth Ganss; Peter J Leedman
Journal:  Front Oncol       Date:  2020-04-09       Impact factor: 6.244

10.  Deferoxamine mesylate improves splicing and GAA activity of the common c.-32-13T>G allele in late-onset PD patient fibroblasts.

Authors:  Emanuele Buratti; Paolo Peruzzo; Luca Braga; Irene Zanin; Cristiana Stuani; Elisa Goina; Maurizio Romano; Mauro Giacca; Andrea Dardis
Journal:  Mol Ther Methods Clin Dev       Date:  2020-11-20       Impact factor: 6.698

View more
  2 in total

1.  Potential biomarkers for retinopathy of prematurity identified by circular RNA profiling in peripheral blood mononuclear cells.

Authors:  Yun Li; Haixiang Zhou; Qian Huang; Wei Tan; Yuting Cai; Zicong Wang; Jingling Zou; Bingyan Li; Shigeo Yoshida; Yedi Zhou
Journal:  Front Immunol       Date:  2022-08-23       Impact factor: 8.786

2.  Identification of Transferrin Receptor 1 (TfR1) Overexpressed in Lung Cancer Cells, and Internalization of Magnetic Au-CoFe2O4 Core-Shell Nanoparticles Functionalized with Its Ligand in a Cellular Model of Small Cell Lung Cancer (SCLC).

Authors:  Rocío Villalobos-Manzo; Emmanuel Ríos-Castro; José Manuel Hernández-Hernández; Goldie Oza; Mauricio A Medina; José Tapia-Ramírez
Journal:  Pharmaceutics       Date:  2022-08-17       Impact factor: 6.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.